Bioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
|
|
- Piers Fleming
- 6 years ago
- Views:
Transcription
1 Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
2 Disclosures I am not Ron Waksman 1
3 Clinical experience with AMS covers peripheral and coronary indications - resumed with a DREAMS first in man study Bare AMS Drug eluting scaffold (DREAMS) Peripheral Coronary BEST-BTK (N=20) PROGRESS (N=63) INSIGHT (N=117) BIOSOLVE-I (N=46) 2 BEST-BTK: Bosiers et al. Vascular Disease Management 2005;2(4):86-91 PROGRESS: Erbel et al. Lancet 2007; 369: INSIGHT: Bosiers et al. Cardiovascular and Interventional Radiology 2008
4 Bioabsorbable Scaffolding: Coronary Studies First in Man Coronary Study of AMS-1: PROGRESS-1 Clinical Performance and Angiographic Results of the Coronary Stenting with Absorbable Metal Stents BIOSOLVE-1 BIOTRONIKS-Safety and Clinical Performance Of the First Drug-Eluting Generation Absorbable Metal Scaffold In Patients with de Novo Lesions in NatiVE Coronary Arteries 3
5 PROGRESS-1 was set-up as a multicenter, coronary FIM study Design Prospective, multi-center, consecutive, non-randomized FIM (First In Man coronary) study Purpose To evaluate the clinical feasibility of the Absorbable Metal Stent in the treatment of a single de novo lesion in a native coronary artery Primary Endpoints Major Adverse Cardiac Events (MACE) at 4 months (cardiac death, nonfatal MI and ischemia driven TLR) Enrollment 63 patients at 8 international clinical sites 4 Source: Erbel et al. Lancet 2007; 369:
6 PROGRESS-1 enrolled patients with short, single de-novo lesions Angiographic and Procedural Characteristics Lesion class (AHA/ACC) Type A 31 (49.2%) Type B1 27 (42.8%) Type B2 5 (7.9%) Type C 0 (0%) Reference vessel diameter Lesion length 2.76 mm Discrete (<10 mm) 23 (36.5%) Tubular (10 20 mm) 40 (63.5%) Moderate to severe calcification 8 (13%) Stents per patient, mean (SD) 1.13 (0.34) Stent length [mm], mean (SD) (1.75) Procedural success 63 (100%) 5 Source: Erbel et al. Lancet 2007; 369:
7 PROGRESS-1 patients showed typical risk factors Baseline Clinical Characteristics Male 44 (70%) Any diabetes 11 (18%) IDDM 3 (5%) History of Smoking 30 (48%) Hypertension 41 (65%) Hyperlipidemia 39 (62%) Stable angina 52 (83%) Unstable angina 6 (10%) Previous CABG 3 (5%) Previous MI 26 (41%) Previous PCI 15 (24%) History of CVA or TIA 1 (2%) History of PAD 4 (6%) 6 Source: Erbel et al. Lancet 2007; 369:
8 PROGRESS-1 confirmed safety in coronary arteries - but moderate TLR In Hospital 4 Months 12 Months N = 63 N = 63 N = 60 n % n % n % MACE (Cardiac death, nonfatal MI, ischemia driven TLR) Death Q-wave MI (new pathol. Q-waves w/ CK or CK-MB elevated) Non Q wave MI (CK 2x above normal with CK-MB elevated) Ischemic Driven TLR Source: Erbel et al. Lancet 2007; 369:
9 DREAMS Drug Eluting Absorbable Metal Scaffold 80x165!m AMS-1 prolong scaffolding time and inhibit cell proliferation Strut geometry Alloy refinement Drug polymer matrix added DREAMS 130x120!m + 1µm matrix!" Proven clinical safety and feasibility!" In 3 clinical studies!" But efficacy had to be improved!" Proprietary Mg-alloy!" Biodegradable polymer!" Paclitaxel!" 6F compatible 8
10 DREAMS provides scaffolding and paclitaxel release up to 3 months Mg alloy Mg degradation product Polymer acute 3 months 6 months 9 months Scaffolding Paclitaxel release Mg + 2H 2 O! Mg(OH) 2 + H 2 Ca(H 2 PO4) 2 Mg Mg!" Initial Mg degradation!" Stable drug carrier layer!" Controlled drug release!" Mg degradation completed!" Drug release completed!" Degradation of polymer ongoing!" Conversion of degradation product completed!" Drug carrier layer degradation completed!" Beginning of structural disintegration 9
11 BIOSOLVE-I enrolled 46 patients in 6 centers Study Design DESIGN: Prospective, multi-centre, first in man trial 46 patients in 6 clinical sites in Germany, Switzerland, the Netherlands and Belgium PRINCIPAL INVESTIGATOR: J. Koolen, Eindhoven, The Netherlands Cohort 1 Cohort 2 PRIMARY ENDPOINT: TLF* cohort 1 at 6 months cohort 2 at 12 months PARTICIPATION CENTERS: Belgium: S. Verheye, Antwerpen Germany: R. Erbel, Essen, M. Haude, Neuss, C. Hehrlein, Freiburg Switzerland: P. Erne, Luzern Clinical follow-up at 1 month Clinical, QCA, IVUS and OCT** follow-up at 6 month Clinical, QCA, IVUS & OCT** follow-up at 12 months Clinical follow-up at 24 & 36 months 10 *Composite of cardiac death, target vessel myocardial infarction and clinically driven TLR ** optional vasomotion testing *** clinical FUP for cohort 1 also at 12 months and for cohort 2 at 6 months
12 Bioabsorbable Scaffolding: Peripheral Studies BEST-BTK First Clinical Application of the Biotronik absorbable metal StenT Below The Knee INSIGHT-1 Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment 11
13 BEST-BTK was set-up as a series of single-center, FIM cases Design Set of 20 FIM (First In Man peripheral) cases, single-center, consecutive, non-randomized Purpose To evaluate the safety and feasibility of the Absorbable Metal Stent in the treatment of infrapopliteal arteries in patients with critical limb ischemia (CLI) Endpoints Primary patency, limb salvage rate Enrollment 20 patients in Belgium were included 12
14 BEST-BTK enrolled patients with critical limb ischemia and short stenoses Demographics Number of patients 20 CLI status Rutherford Class 4 9 (45%) Rutherford Class 5 11 (55%) Lesion Characteristics Lesion length 11 mm [2 20 mm] Average vessel diameter 2.7 mm [2.5 3 mm] Mean diameter stenosis 84% [75 95%] Calcified lesions 14 (70%) Thrombus 3 (15%) 13 Source: Bosiers, et al. Vascular Disease Management 2005;2(4):86-91
15 BEST-BTK results demonstrated promising clinical outcomes Primary patency 3M 89.5% 6M 84.2% 9M 78.9% 12M 73.3% Limb Salvage 3M 100% 6M 94.7% 9M 94.7% 12M 94.7% Primary patency Limb Salvage Number at Risk Time (Days) Number at Risk Time (Days) 14 Source: Bosiers, et al. Vascular Disease Management 2005;2(4):86-91
16 BEST-BTK established first evidence of safety and efficacy for AMS!" AMS implantation is safe!" AMS provides good vessel scaffolding!" AMS is absorbed as intended (CFDU, MR)!" AMS remains patent This first clinical experience indicated that AMS is a safe and effective therapy for infrapopliteal stenting 15
17 INSIGHT-1 was set-up as a randomized study against PTA below-the-knee Design Prospective, multi-center, randomized clinical trial Purpose Assess the efficacy and safety of AMS-1 for the treatment of infrapopliteal lesions in patients with CLI Primary Endpoints!" Patency of the AMS determined with intra-arterial Digital Subtraction Angiography (DSA) at 6 month follow-up!" Complications 1 month post-procedure (major amputations defined as amputations at or above the ankle or any cause of death) Enrolment 117 patients in 15 sites, finalized
18 INSIGHT-1 enrolled CLI patients with short lesions below the knee Demographics PTA Only AMS p value Number of patients Male 71.9% 51.7% 0.04 CLI status Rutherford Class % 26.7% Rutherford Class % 73.3% 0.87 Lesion Characteristics Lesion length (mm) 12.5± ± RVD (mm) 2.7± ± MLD (mm) 0.8± ± Percent Diameter Stenosis (%) 68.7± ± Calcification (%) 45.3% 48.6%
19 A typical INSIGHT-1 case shows good immediate results and slight lumen loss at 6 months Angiographic evolution in AMS case Pre Post 6M 18 Source: Bosiers, CIRSE 2008
20 INSIGHT-1 clinical outcomes showed no difference between PTA and AMS Primary patency 2M 91.2% 4M 89.6% 6M 80.2% Limb Salvage 2M 93.2% 4M 91.4% 6M 87.6% ITT: Patency PTA 58% vs AMS 31.8% (p=0.013). 19 Source: Bosiers, Cardiovascular and Interventional Radiology 2008, OnlineFirst
21 INSIGHT-1 failed to show superiority over PTA!" AMS was successfully used in cases with suboptimal PTA results (bail-out cases)!" The study confirmed the safety of the AMS technology (procedural and device success)!" The clinical outcome between the PTA and AMS groups is comparable (limb salvage, Rutherford status)!" AMS shows lower patency compared to PTA 20
22 Summary!" Absorbable metal scaffold is safe and feasible!" A prolongation in scaffolding time as well as an antiproliferative drug were added to DREAMS!" BIOSOLVE-I, the FIM study for DREAMS, included 46 patients in 6 centers!" Results of the first cohort of BIOSOLVE-I will be presented at EuroPCR
Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up
Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up Ron Waksman, MD FACC FSCAI FESC Professor of Medicine, Georgetown University Director, Cardiovascular Research
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationMagmaris Stent (Biotronik) A Pichard, Ron Waksman. Medstar Washington Hospital Center Washington, DC
Magmaris Stent (Biotronik) A Pichard, Ron Waksman. Medstar Washington Hospital Center Washington, DC Conflict of Interest None for this presentation Downside of Metallic Stents 1. Restenosis No longer
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationBIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions
BIOFLOW-III an all comers registry with a Sirolimus Eluting Stent: Presentation of 1-Year TLF Data in patients with complex lesions Johannes Waltenberger, MD, F.E.S.C. Uniklinik Münster Münster, Germany
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationSpecificities for infrapopliteal stents
Specificities for infrapopliteal stents Nicolas Diehm, M.D. Swiss Cardiovascular Center Clinical and Interventional Angiology University Hospital Bern, Switzerland Disclosures Speaker`s Bureau: MEDRAD,
More informationThe role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium
The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium Disclosures Speaker name: Frank Vermassen I have the following potential
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationThe latest evidences from the DES trials in peripheral arterial disease
The latest evidences from the DES trials in peripheral arterial disease Michael D. Dake, MD Thelma and Henry Doelger Professor Stanford University School of Medicine Disclosure Speaker name: Michael D.
More informationJanuary 23, Vascular and oncological interventional radiology Paris Descartes University
January 23, 2019 First time data release: Paclitaxel-coated balloon in below-the-knee lesions: 6-months results from the Ranger BTK single center study Dr. Costantino Del Giudice Prof Marc Sapoval Vascular
More informationPresent & future of below the knee stenting
Session 5 Below the knee arteries & limb salvage Present & future of below the knee stenting M. Bosiers K. Deloose P. Peeters 1 PRESENT Clinical perspective whom to treat CRITICAL LIMB ISCHEMIA (CLI) 0
More informationΒιοαποδομήσιμα Στεφανιαία Ικριώματα με βάση το μαγνήσιο. Magnesium Bioresorbable Coronary Scaffolds
Βιοαποδομήσιμα Στεφανιαία Ικριώματα με βάση το μαγνήσιο. Magnesium Bioresorbable Coronary Scaffolds Βάιος Π. Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Ερρίκος Ντυνάν HC Δεν υπάρχει σύγκρουση συμφερόντων
More informationBIOFLOW V Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents
Comparison of UltraThin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus- Eluting Durable Polymer Stents David E Kandzari, MD; Laura Mauri, MD, MSc; Jacques Koolen, MD, PhD; Joseph M Massaro,
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationDealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?
Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer? Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC 2017 January 25 th 2017 Disclosure
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationNOBORI 2 Trials One Year Clinical Outcomes
NBRI 2 Trials ne Year Clinical utcomes Dr G.B. Danzi spedale Maggiore Policlinico Milano, Italy INTRDUCTIN Pivotal DES trials enrolled restricted patient population, not truly representative of every day
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the Everolimus Eluting Stent Bernard Chevalier
More informationFANTOM II trial: Clinical results from the Fantom Sirolimus-Eluting BRS. Norbert Frey, MD University of Kiel, Germany
FANTOM II trial: Clinical results from the Fantom Sirolimus-Eluting BRS Norbert Frey, MD University of Kiel, Germany Potential conflicts of interest Speaker's name: Dr. Norbert Frey I have the following
More informationProspective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results
Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results Stefan Verheye, MD PHD ZNA Middelheim Antwerp, Belgium Potential
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationMaking BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
More informationReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update
ReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update Dr. David Muller St Vincent s Hospital Sydney, Australia 0 Potential conflicts of interest Speaker's name: Dr. David Muller I do not have
More informationThe Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results
The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results Dr. VIVEK GUPTA MD, DM, FICC, FIC France Senior Interventional Cardiologist Indraprastha Apollo
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationUpdate from the Tryton IDE study
Update from the Tryton IDE study Maciej Lesiak EBC 2015 - Athens The Tryton Bifurcation Trial: A randomized comparison of a provisional one-stent vs. a dedicated two-stent strategy for true bifurcation
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More informationThe essentials for BTK procedures: wires, balloons, what else
A comprehensive approach to diabetic patient Tx The essentials for BTK procedures: wires, balloons, what else Dai-Do Do Clinical and Interventional Angiology Cardiovascular Department Disclosure Speaker
More informationDrug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
More informationBioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationSingle Center Consecutive Registry Of The New Atrium Flyer Coronary Stent System
Single Center Consecutive Registry Of The New Atrium Flyer Coronary Stent System TO Kjellevand, AJ Tofte Department of Cardiology, Rikshospitalet, NO-0027 Oslo Norway 19th Annual Interventional Cardiology
More informationDISRUPT CAD. Todd J. Brinton, MD Clinical Associate Professor of Medicine Adjunct Professor of Bioengineering Stanford University
DISRUPT CAD A multicenter, prospective, single-arm study of percutaneous Lithoplasty prior to stent implantation in heavily calcified coronary lesions Todd J. Brinton, MD Clinical Associate Professor of
More informationDISAPPEARING STENT: IS THE TIME APPEARED?
DISAPPEARING STENT: IS THE TIME APPEARED? Carlo Cernetti Chief Cardiology Division San Giacomo Hospital Castelfranco Veneto (TV) 1 THE BEGINNING START randomized study (n=452) Long-term follow-up The benefit
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationSide branch occlusion in 500 ABSORB BVS
Side branch occlusion in 500 ABSORB BVS Clinical implications and Solutions Robert-Jan van Geuns, MD, PhD Associate Professor,Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands On behalf
More informationPotential Conflicts of Interest
DES-BTK: A Prospective, Double-Blind Randomized Trial of Polymer-Free Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Infrapopliteal Disease Aljoscha Rastan, MD, Gunnar Tepe, MD,
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationTRIAS HR Pilot Study
Late Breaking Clinical Trials TCT, October 22 nd 27, Washington, USA TRIAS HR Pilot Study RCT comparing Genous EPC capturing stent with Taxus Paclitaxel eluting stent Robbert J de Winter MD PhD FESC Academic
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier
More informationMid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationIMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of
IMPORTANT INFORMATION: These materials are intended to describe common clinical considerations and procedural steps for the on-label use of referenced technologies as well as current standards of care
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationILLUMENATE FIH Direct DCB Cohort 12-Month Results
ILLUMENATE FIH Direct DCB Cohort 12-Month Results Stephan Duda Berlin Study Investigators: H. Schröder (PI), B. Lux, F. Rücker, M. Martorana, D. Meyer, H. Hartmann, S. Duda Disclosure Speaker name: S.
More informationSummit TCT Asia Pacific
Summit TCT Asia Pacific Future Horizons in Coronary Stenting Jacques Koolen Md PhD FSCAI Catharina Hospital Eindhoven Netherlands Where are we? Where do we want to go? TODAY - the Drug Eluting Stent DES
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationSUPERSUB Trial: 1-yr outcomes of SUPERa SUBintimal stenting in CLI Patients
SUPERSUB Trial: 1-yr outcomes of SUPERa SUBintimal stenting in CLI Patients Dr. L.M. Palena, MD Interventional Radiology Unit Foot & Ankle Clinic Policlinico Abano Terme (PD), ITALY Disclosure I have the
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationPES BTK 70 : 12 m results with a paclitaxelcoated self-expanding stent in BTK arteries
LINC 2015, Leipzig A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist OLV Hospital, Aalst Lieven Maene Roel Beelen R.Z. Heilig
More informationOCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD
OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter Patrick Muck, MD Chief, Division of Vascular Surgery Good Samaritan Hospital Cincinna
More informationEBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb
EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb A. Medina Servicio de Cardiología Hospital Universitario de Gran Canaria Dr. Negrín Islas Canarias (Spain) Provisional
More informationDierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany
The RANGER clinical trial programme: 12-month results from the RANGER RCT and first look at the COMARE I study of RANGER vs. IN.PACT for femoropopliteal lesions Dierk Scheinert, MD Department of Angiology
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST In the last five years, I received research grants or speaker fees or I am/was consultant for: Abbott Vascular, Asahi, Astra Zeneca, AVI, Boston Scientific, Biotronik,
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationAngiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions
244 U. Gerk, B. Leithäuser, U. Schäfer, F. Jung, J.-W. Park Applied Cardiopulmonary Pathophysiology 14: 244-249, 2010 Angiographic long-term results after implantation of the paclitaxel-eluting coronary
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationLutonix DCB in BTK Update on the BTK real world registry and RCT
Lutonix DCB in BTK Update on the BTK real world registry and RCT Prof. Dr. med. Dierk Scheinert Department of Interventional Angiology University Hospital Leipzig Disclosures Speaker: Prof. Dr. med. Dierk
More informationUpdate from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationThe Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System
The Clinical Evaluation of the Medtronic AVE Driver Coronary Stent System A prospective, multicenter, non randomized study to evaluate the safety and efficacy of the Medtronic AVE Driver Coronary Stent
More informationOn behalf of the DURABILITY Investigators:
On behalf of the DURABILITY Investigators: S. Müller-Hülsbeck 1, M. Bosiers 2, G. Torsello 3, D. Scheinert 4, H. Gissler 5, J. Ruef 6, T. Jahnke 7, P. Peeters 8, K. Daenens 9, J. Lammer 1 1 Ev.-Luth. Diakonissenanstalt
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More information4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters
Drug-eluting technology in the SFA and Popliteal David Paul Slovut, MD, PhD Associate Professor of Medicine and Surgery Co-director of TAVR program Director of Advanced Intervention Faculty Disclosure
More informationCOMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions Dierk Scheinert Department of Angiology University Hospital Leipzig, Germany Disclosure
More informationFirst time data release: Initial experience with the temporary Spur Stent System: DEEPER Trial first-in-man results Jihad A. Mustapha, MD, FACC,
First time data release: Initial experience with the temporary Spur Stent System: DEEPER Trial first-in-man results Jihad A. Mustapha, MD, FACC, FSCAI Associate Professor of Medicine Michigan State University,
More informationThe Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience
The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have
More informationNeuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationFAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS
Coronary Physiology In The Cathlab FAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS Educational Training Program ESC European Heart House april 7th 9th 2011 Nico H.J.Pijls, MD, PhD Catharina Hospital,
More informationThe LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint
The LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint Dr. Ulrich Beschorner Universitäts Herzzentrum Freiburg
More informationINTERVENTIONAL CARDIOLOGY Bioresorbable Stents Update: Similarities. Generation BVS
INTERVENTIONAL CARDIOLOGY 2017 32 ND ANNUAL INTERNATIONAL SYMPOSIUM Bioresorbable Stents Update: Similarities and Differences in Comparison to First Generation BVS Dariusz Dudek Institute of Cardiology
More informationClinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry Alexander Zimmermann Department of Vascular and Endovascular Surgery Klinikum rechts der Isar
More informationElement Clinical Program Perseus Late Breaking News and the Platinum Study Design
Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP, FACC, FCSANZ, FSCAI, FAHA, FAPSIC Professor and Director of Monash HEART
More information12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationShockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany
Shockwave Medical Lithoplasty Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany Disclosure Speaker name: Thomas Zeller, MD I have the following potential conflicts of interest
More informationBiodegradable Stents An update and work-in
Biodegradable Stents An update and work-in in-progress Department of Cardiology, Hideo Tamai, M.D. Metallic stents... Background induce a varing degree of thrombogenesis eg, subacute thrombosis in complex
More informationThe TANGO Trial: A phase II below-the-knee study investigating the adventitial micro-infusion of Temsirolimus after PTA or atherectomy
The TANGO Trial: A phase II below-the-knee study investigating the adventitial micro-infusion of Temsirolimus after PTA or atherectomy Ian Cawich, MD Arkansas Heart Hospital Little Rock, Arkansas, USA
More information